Joshua Richter

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 41

Top Topics

Multiple Myeloma

Systematic Review

Direct Oral Anticoagulants

Acute Lymphoblastic Leukemia

Top Venues

American journal of hematology

British journal of haematology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Bruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, Joshua Richter
Soluble B-cell maturation antigen in multiple myeloma. American journal of hematology 99 (4) (2024)
Santiago Thibaud, Ryan L Subaran, Scott Newman, Alessandro Lagana, David T Melnekoff, Saoirse Bodnar, Meghana Ram, Zachry Soens, William Genthe, Tehilla E Brander, Tarek H Mouhieddine, Oliver Van Oekelen, Jane Houldsworth, Hearn Jay Cho, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa J Sanchez, Ajai Chari, Erin Laverne Moshier, Sundar Jagannath, Samir S Parekh, Kenan Onel
Multiple Myeloma Risk and Outcomes are Associated with Pathogenic Germline Variants in DNA Repair Genes. Blood cancer discovery (2024)
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzch, Rachid C Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca W Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquin Martinez Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D Yancopoulos, L Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S Kroog, Yariv Houvras, Madhav V Dhodapkar
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzch, Rachid C Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca W Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquin Martinez Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D Yancopoulos, L Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S Kroog, Yariv Houvras, Madhav V Dhodapkar
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Thomaz Alexandre Costa, Nicole Felix, Joshua Richter
'X' marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma. British journal of haematology 205 (2) (2024)
Bruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, Nicole Felix, Carlyn Rose Tan, Neha Korde, Joshua Richter
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis. American journal of hematology 99 (6) (2024)
Bruno Almeida Costa, Thomaz Alexandre Costa, Kevin Pak, Aesha Patel, Nicole Felix, Tarek H Mouhieddine, Joshua Richter
Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis. American journal of hematology (2024)
Joshua Richter
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T. Blood cancer journal 14 (1) (2024)
Thomaz Alexandre Costa, Nicole Felix, Joshua Richter
'X' marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma. British journal of haematology 205 (2) (2024)
Bruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, Nicole Felix, Carlyn Rose Tan, Neha Korde, Joshua Richter
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis. American journal of hematology 99 (6) (2024)
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzch, Rachid C Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca W Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquin Martinez Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D Yancopoulos, L Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S Kroog, Yariv Houvras, Madhav V Dhodapkar
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Csaba Siffel, Joshua Richter, Colin Anderson-Smits, Marta Kamieniak, Kaili Ren, Drishti R Shah, Matthew S Davids
Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study. Annals of hematology (2024)
Joshua Richter
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T. Blood cancer journal 14 (1) (2024)
Bruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, Joshua Richter
Soluble B-cell maturation antigen in multiple myeloma. American journal of hematology 99 (4) (2024)
Bruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, Nicole Felix, Carlyn Rose Tan, Neha Korde, Joshua Richter
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis. American journal of hematology (2024)
Bruno Almeida Costa, Thomaz Alexandre Costa, Kevin Pak, Aesha Patel, Nicole Felix, Tarek H Mouhieddine, Joshua Richter
Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis. American journal of hematology 99 (7) (2024)
Bruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, Joshua Richter
Soluble B-cell maturation antigen in multiple myeloma. American journal of hematology 99 (4) (2024)
Joshua Richter
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T. Blood cancer journal 14 (1) (2024)
Thomaz Alexandre Costa, Nicole Felix, Joshua Richter
'X' marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma. British journal of haematology (2024)
Bruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, Joshua Richter
Soluble B-cell maturation antigen in multiple myeloma. American journal of hematology (2024)
Bruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, Nicole Felix, Carlyn Rose Tan, Neha Korde, Joshua Richter
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis. American journal of hematology 99 (6) (2024)
Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman, Attaya Suvannasankha, Jeffrey A Zonder, Mansi R Shah, Suzanne Lentzch, Rachid C Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca W Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquin Martinez Lopez, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D Yancopoulos, L Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S Kroog, Yariv Houvras, Madhav V Dhodapkar
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (22) (2024)
Bruno Almeida Costa, Thomaz Alexandre Costa, Kevin Pak, Aesha Patel, Nicole Felix, Tarek H Mouhieddine, Joshua Richter
Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis. American journal of hematology 99 (7) (2024)
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati, Sudhir Manda, Roger M Lyons, Habte A Yimer, Dasha Cherepanov, Eric Lloyd, Presley Whidden, Joshua Richter
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management. Blood cancer journal 13 (1) (2023)
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, Lisa Avery, Alaina Lurie, Alex Lieberman-Cribbin, Hearn Jay Cho, Samir S Parekh, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa J Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood cancer discovery (2023)
Urvi A Shah, Erin Laverne Moshier, Andriy Derkach, Yuanhui Huang, Sham Mailankody, Carlyn Rose Tan, Kylee H Maclachlan, Malin L Hultcrantz, Neha Korde, Hani Hassoun, Santiago Thibaud, Larysa Sanchez, Cesar Rodriguez, Shambavi Richard, Joshua Richter, Adriana Rossi, Hearn Jay Cho, Alexander M Lesokhin, Ajai Chari, Saad Z Usmani, Sundar Jagannath, Samir Parekh, Emily Jane Gallagher
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups. Blood advances (2023)
Joshua Richter
T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails! British journal of haematology 204 (3) (2023)
Joshua Richter, Peggy L Lin, Viviana Garcia-Horton, Patricia Guyot, Erin Singh, Zheng-Yi Zhou, Mark Sievert, Riley Taiji
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma. Cancer medicine (2023)
Joshua Richter
T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails! British journal of haematology (2023)
Joshua Richter, Darren Pan, Taylor Salinardi, Megan S Rice
Real-world multiple myeloma front-line treatment and outcomes by transplant in the United States. EJHaem 4 (4) (2023)
Joshua Richter
T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails! British journal of haematology 204 (3) (2023)
Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, Suman Kambhampati, Joshua Richter, Rafat Abonour, Hans C Lee, Michael Stokes, Kaili Ren, Dawn Marie Stull, Dasha Cherepanov, Kimberly Bogard, Stephen J Noga, Saulius Girnius
In -class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. Future oncology (London, England) (2023)
Bruno Almeida Costa, Tarek H Mouhieddine, Joshua Richter
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. Targeted oncology 17 (4) (2022)
Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, Adolfo Aleman, Violetta V Leshchenko, David T Melnekoff, Sarita Agte, Joy J Jiang, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Laganà, Samir S Parekh
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO precision oncology 6 (2022)
Guido Lancman, Erin Moshier, Hearn Jay Cho, Samir Parekh, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Sundar Jagannath, Ajai Chari
Trial designs and endpoints for immune therapies in multiple myeloma. American journal of hematology (2022)
Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, Jeanne Li, Yogita Ghodke-Puranik, Guido Lancman, Santiago Thibaud, Darren Pan, Sridevi Rajeeve, Sarita Agte, Adolfo Aleman, Larysa Sanchez, Shambavi Richard, Adriana Rossi, Joshua Richter, Hearn Jay Cho, Cesar Rodriguez, Alessandro Lagana, Erin L Moshier, Ajai Chari, Sundar Jagannath, Samir Parekh
Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. Blood advances (2022)
Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Therapeutic advances in hematology 12 (2021)
Larysa Sanchez, Alexandra Dardac, Deepu Madduri, Shambavi Richard, Joshua Richter
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. Therapeutic advances in hematology 12 (2021)
Sherry Bhalla, David T Melnekoff, Adolfo Aleman, Violetta V Leshchenko, Paula Restrepo, Jonathan J Keats, Kenan Onel, Jeffrey R Sawyer, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Joel T Dudley, Sundar Jagannath, Alessandro Lagana, Samir S Parekh
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Science advances 7 (47) (2021)
Joshua Richter, Vamshi Ruthwik Anupindi, Jason Yeaw, Suneel Kudaravalli, Stojan Zavisic, Drishti Shah
Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Joshua Richter, Deepu Madduri, Shambavi Richard, Ajai Chari
Selinexor in relapsed/refractory multiple myeloma. Therapeutic advances in hematology 11 (2020)